Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

@article{Byrd2002PretreatmentCA,
  title={Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).},
  author={John C. Byrd and Krzysztof Mr{\'o}zek and Richard K. Dodge and Andrew J Carroll and Colin G. Edwards and Diane C. Arthur and Mark J. Pettenati and Shivanand R. Patil and Kathleen W. Rao and Michael S. Watson and Prasad R. K. Koduru and Joseph Moore and Richard M Stone and Robert J. Mayer and Eric J. Feldman and Frederick R. Davey and Charles A Schiffer and Richard A. Larson and Clara D. Bloomfield},
  journal={Blood},
  year={2002},
  volume={100 13},
  pages={
          4325-36
        }
}
  • John C. Byrd, Krzysztof Mrózek, +16 authors Clara D. Bloomfield
  • Published 2002
  • Medicine
  • Blood
  • We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-year overall survival (OS). All patients received similar induction therapy. Median follow-up for surviving patients was 8.3 years. Nonprioritized cytogenetics distinguished t(8;21) and inv(16)/t(16;16) as conferring a significantly better prognosis than normal… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Primary study objective is the evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in… Expand
    ConditionsLeukemia, Myeloid
    InterventionProcedure
    INTERVENTIONAL CLINICAL TRIAL
    Pilot, multicentric, open-label, single-arm, phase I-II clinical trial to evaluate the safety and efficacy of a novel Umbilical Cord Blood Transplantation (UCBT) platform, that consists… Expand
    ConditionsLeukemia
    InterventionOther
    INTERVENTIONAL CLINICAL TRIAL
    [Study Objectives] - To evaluate the efficacy of allogeneic hematopoietic cell transplantation (HCT) in patients with acute lymphoblastic leukemia (ALL) in the first or… Expand
    ConditionsAcute Lymphoid Leukemia
    InterventionProcedure
    OBSERVATIONAL CLINICAL TRIAL
    Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It… Expand
    ConditionsAcute Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, (+1 more)
    InterventionGenetic

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 945 CITATIONS, ESTIMATED 46% COVERAGE

    Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

    VIEW 9 EXCERPTS
    CITES METHODS & BACKGROUND
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2000
    2020

    CITATION STATISTICS

    • 42 Highly Influenced Citations

    • Averaged 48 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 72 REFERENCES